BMS’ Triple Regimen Receives Positive CHMP Recommendation for its Approval to Treat R/R Multiple Myeloma in Europe

 BMS’ Triple Regimen Receives Positive CHMP Recommendation for its Approval to Treat R/R Multiple Myeloma in Europe

Shots:

  • The opinion is based on P-II ELOQUENT-3 study assessing Empliciti (elotuzumab) + pomalidomide and dexamethasone (EPd) vs pomalidomide + dexamethasone (Pd) in 117 patients in a ratio (1:1) with multiple myeloma prior treated with 2L+ therapies including lenalidomide and a proteasome inhibitor
  • The CHMP recommendation will be reviewed by the European Commission to approve the combination therapy in the EU. The CHMP’s positive opinion further validates the Empliciti-based combination for patients with MM, r/r to prior therapies
  • Empliciti is an immunostimulatory Ab targeting SLAMF7 and has received the US FDA’s approval in combination with lenalidomide and dexamethasone for MM in 2015, co-developed by BMS and AbbVie with BMS being solely responsible for commercialization activities

Click here to­ read full press release/ article | Ref: BMS | Image: Financial News

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post